Pharmacogenomics of statin response

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 6, 2008, Pages 555-561

  Mangravite, L M ^a   Wilke, R A ^b   Zhang, J ^a   Krauss, R M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cardiovascular disease; LDL cholesterol; Pharmacogenomics; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG WITHDRAWAL; ETHNICITY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LOW DRUG DOSE; MONOTHERAPY; MUSCLE DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; PHARMACOGENOMICS; RACE DIFFERENCE; RESPONSE VARIABLE; REVIEW; RHABDOMYOLYSIS; TREATMENT RESPONSE;

ANTICHOLESTEREMIC AGENTS; GENOME, HUMAN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 57349176121     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110(2):227-239.
2. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. J Am Med Assoc (1999) 282(24):2340-2346.
3. Shepherd J, Cobbe SM, Ford I, Isle CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 333(20):1301-1307.
4. Yee HS, Fong NT: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother (1998) 32(10):1030-1043.
5. Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI, Nickerson DA, Yang H, Saad M, Krauss RM: Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: The Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 97(6):843-850.
6. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther (2005) 78(4):330-341.
7. Wu J, Province MA, Coon H, Hunt SC, Eckfeldt JH, Arnett DK, Heiss G, Lewis CE, Ellison RC, Rao DC, Rice T, Kraja AT: An investigation of the effects of lipid-lowering medications: Genome-wide linkage analysis of lipids in the HyperGEN study. BMC Genet (2007) 8:60.
8. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY: Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J Stroke Cerebrovasc Dis (2007) 16(4):160-166.
9. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 37(2):161-165.
10. Rader DJ, Cohen J, Hobbs HH: Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. J Clin Invest (2003) 111(12):1795-1803.
11. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr Opin Lipidol (2007) 18(4):409-414.
12. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J (2006) 6(6):360-374.
13. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. J Am Med Assoc (2003) 289(13):1681-1690.
14. Tobert JA: Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov (2003) 2(7):517-526.
15. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JPD, Stein EA: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med (2003) 163(5):553-564.
16. Wilke RA, Mareedu RK, Moore JH: The pathway less traveled - moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr Pharmacogenomics Personalized Medicine (2008) 6(3):150-159.
17. Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Westendorp RC et al: Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis (2008) 200(1):109-114.
18. Tavintharan S, Lim SC, Chan YH, Sum CF: Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab (2007) 9(1):81-86.
19. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res (2007) 55(4):310-317.
20. Anagnostopoulou K, Kolovou G, Kostakou P, Mihas C, Mikhailidis D, Cokkinos DV: Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother (2007) 8(15):2459-2463.
21. Javorsky M, Gasperikova D, Ukropec J, Sedlakova B, Riecansky I, Krizanova O, Sebokova E, Dobrikova M, Klimes I, Tkac I: Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease. Wien Klin Wochenschr (2007) 119(15-16):476-482.
22. Ying S, Sun YM, Liu XM, An CY, Gao YY: Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients. Biochem Biophys Res Commun (2007) 363(2):395-398.
23. Polisecki E, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Blauw GJ, Westendorp RG, de Craen AJ et al: Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis (2008) 200(1):95-101.
24. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc (2004) 291(23):2821-2827.
25. Goodarzi MO, Taylor KD, Scheuner MT, Antoine HJ, Guo X, Shah PK, Rotter JI: Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J (2007) 7(1):66-73.
26. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D, Saad M et al: Variation in the 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation (2008) 117(12):1537-1544. •• This study described the genetic contribution of racial differences to statin response.
27. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J (2005) 5(6):352-358.
28. Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, Meyer JM: Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res (2007) 48(9):2072-2078.
29. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM: Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation (2008) 118(4):355-362. •• This study identified a splice variant in HMGCR that associated with statin efficacy.
30. Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH: Variation in Niemann-Pick C1-Like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin Endocrinol (2008) 69(1):45-51. • This study was one of the first attempts to identify the functional relationship between genotype and clinical response.
31. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev (2002) 54(10):1271-1294.
32. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther (2006) 10(3):135-151.
33. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM: Effect of genetic variation in the organic cation transporter 1 (Oct1) on metformin action. J Clin Invest (2007) 117(5):1422-1431.
34. Kim KA, Park PW, Lee OJ, Kang DK, Park JY: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol (2007) 47(1):87-93.
35. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol (2004) 93(1):104-107.
36. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 14(8):523-525.
37. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Michael Stein C, Kim RB: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 17(8):647-656.
38. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (2007) 82(5):541-547.
39. Kivisto KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res (2007) 24(2):239-247. • An excellent review of the association between pravastatin response and genetic variation in solute carriers.
40. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 82(6):726-733.
41. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, Wang LC et al: SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multipledose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol (2007) 64(3):346-352.
42. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 45:89-118.
43. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol (2005) 16(6):624-629.
44. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM: Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol (2000) 35(1):89-95.
45. Puccetti L, Bruni F, Pasqui AL, Pastorelli M, Ciani F, Palazzuoli A, Acampa M, Auteri A: Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia. Eur J Clin Invest (2008) 38(1):11-16.
46. Trompet S, Pons D, DE Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I et al: Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: The PROSPER study. Ann NY Acad Sci (2007) 1100:189-198.
47. Kosmidou I, Moore JP, Weber M, Searles CD: Statin treatment and 3′ polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol (2007) 27(12):2642-2649.
48. CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circ Res (2007) 100(1):50-60.
49. Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J: Statins reduce macrophage inflammatory protein-1α expression in human activated monocytes. Clin Exp Pharmacol Physiol (2006) 33(12):1144-1149.
50. Ilveskoski E, Lehtimaki T, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Laippala P, Karhunen PJ, Knuuti J: Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype. Scand J Clin Lab Invest (2007) 67(7):723-734.
51. Kiliszek M, Burzynska B, Styczynski G, Maciag M, Rabczenko D, Opolski G: A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment. Clin Chem Lab Med (2007) 45(7):839-842.
52. Nieminen T, Knuuti J, Hamelahti P, Kahonen M, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Jokela H, Lehtimaki T: Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol (2007) 47(2-3):113-117.
53. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS: Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch Med Res (2007) 38(4):403-410.
54. Deakin S, Guernier S, James RW: Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet Genomics (2007) 17(6):451-457.
55. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 40(2):189-197.
56. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresen S, Hirschhorn JN, Daly MJ, Hughes TE et al: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 316(5829):1331-1336.
57. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Naijjar SS, Stringham HM, Strait J et al: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 40(2):161-169.
58. Kooner JS, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, Gomez Perez FJ, Frazer KA, Elliott P, Scott J, Milos PM et al: Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 40(2):149-151.
59. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M et al: LDL-cholesterol concentrations: A genome-wide association study. Lancet (2008) 371(9611):483-491.
60. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, Iakoubova OA, Pullinger CR, Cassano J, Aouizerat BE, Fenwick RG, Reitz RE et al: Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 77(4):596-605.
61. Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ, Pfeffer MA et al: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 51(4):435-443.
62. Shiffman D, Chasman DI, Zee RY, Iakoubova OA, Louie JZ, Devlin JJ, Ridker PM: A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol (2008) 51(4):444-448.
63. Shiffman D, O'Meara ES, Bare LA, Rowland CM, Louie JZ; Arellano AR, Lumley T, Rice K, Iakoubova O, Luke MM, Young BA et al: Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2008) 28(1):173-179.
64. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E et al: Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: Results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 51(4):449-455. •• The collective research by these investigators led to the identification of the first genetic predictor of statin response with potential utility as a clinical diagnostic marker.
65. Sabatine MS, Ploughman L, Simonsen KL, Iakoubova OA, Kirchgessner TG, Ranade K, Tsuchihashi Z, Zerba KE, Long DU, Tong CH, Packard CJ et al: Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol (2008) 28(3):562-567.
66. Chan J, Hui RL, Levin E: Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother (2005) 39(10):1611-1616.
67. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM: Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat Rev Drug Discov (2007) 6(11):904-916.
68. McClure DL, Valuck RJ, Glanz M, Hokanson JE: Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf (2007) 16(2):132-143.
69. McKenney JM, Davidson MH, Jacobson TA, Guyton JR: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 97(8A):89C-94C.
70. Teichholz LE: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med (2003) 138(12):1008; author reply 1008-1009.
71. Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol (2006) 97(8A):69C-76C.
72. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med (2002) 137(7):581-585.
73. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimaki T, von Bergmann K, Lutjohann D, Laaksonen R: High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Clin Pharmacol Ther (2005) 78(1):60-68.
74. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiycuk EB: Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol (2006) 210(1):94-102.
75. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH: The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther (2005) 78(5):551-558.
76. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K: A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet (2004) 19(6):453-455.
77. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA: Genetic determinants of statin intolerance. Lipids Health Dis (2007) 6:7.
78. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve (2006) 34(2):153-162. • A thoughtful analysis of known genetic determinants of myopathy in relation to statin-induced myopathy.
79. Wilke RA, Moore JH, Burmester JK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics (2005) 15(6):415-421.
80. Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat Rev Drug Discov (2005) 4(11):911-918.
81. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ: CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics (2007) 17(9):695-707.
82. Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armburst U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivisto KT, Lang T: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics (2006) 16(11):801-808.
83. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med (2008) 359(8):789-799. •• This study described the identification of the first genetic predictor of statin-induced myopathy.
84. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, Shirai K, Inoue I: A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet (2004) 49(10):582-585.
85. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lutjohann D, Smet J, Van Coster R, Seppanen-Laakso T, Lehtimaki Y et al: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE (2006) 1:e97. •• This study identified biological mechanisms involved in statin myotoxicity.
86. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, Raab CE, Yu NX, Lankas GR, Frederick CB: Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol (2004) 194(1):10-23.
87. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA (1998) 95(4):1369-1374.
88. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther (2000) 68(4):391-400.
89. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol (2006) 291(6):C1208-C1212.
90. Ruano G, Thompson PD, Windemuth A, Seip RL, Dande A, Sorokin A, Kocherla M, Smith A, Holford TR, Wu AH: Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve (2007) 36(3):329-335.
91. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH: The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest (2007) 117(12):3940-3951. •• This study identified a potentially important mechanism for statin-induced myotoxicity.
92. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y: When good drugs go bad. Nature (2007) 446(7139):975-977.
93. Peissig P, Sirohi E, Berg RL, Brown-Switzer C, Gherbranious N, McCarty CA, Wilke RA: Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol (2007) 100(4):286-288. • This study utilized a novel strategy to define statin efficacy through clinical practice for future validation of the diagnostic power of genetic markers identified from controlled statin trials.